SLNSW-Ibrutinib plus obinutuzumab versus chlorambucil p...-TN_cdi_proquest_journals_2162985913

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Full title: Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Author/creator: Moreno, Carol, Greil, Richard, Demirkan, Fatih, Tedeschi, Alessandra, Anz, Bertrand, Larratt, Loree, Simkovic, Martin, Samoilova, Olga, Novak, Jan, Ben-Yehuda, Dina, Strugov, Vladimir, Gill, Devinder, Gribben, John G, Hsu, Emily, Lih, Chih-Jian, Zhou, Cathy, Clow, Fong, James, Danelle F, Styles, Lori, Flinn, Ian W.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2162985913

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2162985913

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    Record identifier

    TN_cdi_proquest_journals_2162985913

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2162985913

    Share

    Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2162985913

    Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    Full title

    Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    Author / Creator

    Moreno, Carol ; Greil, Richard ; Demirkan, Fatih ; Tedeschi, Alessandra ; Anz, Bertrand ; Larratt, Loree ; Simkovic, Martin ; Samoilova, Olga ; Novak, Jan ; Ben-Yehuda, Dina ; Strugov, Vladimir ; Gill, Devinder ; Gribben, John G ; Hsu, Emily ; Lih, Chih-Jian ; Zhou, Cathy ; Clow, Fong ; James, Danelle F ; Styles, Lori ; Flinn, Ian W

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2019, Vol.20 (1), p.43-56

    Record Identifier

    TN_cdi_proquest_journals_2162985913

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antimitotic agents Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cardiac arrhythmia Chemotherapy Chlorambucil Chlorambucil - administration & dosage Chlorambucil - adverse effects Chlorambucil - therapeutic use Chronic lymphocytic leukemia Cytogenetics Dyspnea Female Humans Hyperglycemia Immunotherapy Intention to Treat Analysis Intravenous administration Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Lymphoma Male Monoclonal antibodies Mutation Neutropenia Neutrophils Oncology Patients Product development Progression-Free Survival Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Skin Survival Targeted cancer therapy Thrombocytopenia Treatment Outcome

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2162985913

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2162985913

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections